This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Elevance Health Stock Has More to Offer: Should You Hold on Tight?
by Zacks Equity Research
In the commercial category, an increase in individual as well as employer group fee-based memberships will continue supporting ELV's medical membership numbers.
AngioDynamics Stock Falls Despite CE Mark for Auryon System
by Zacks Equity Research
ANGO's Auryon Atherectomy System earns CE Mark, which expands its European market reach and enhances PAD treatment with advanced laser technology.
Ensign Adds 8 Facilities in Kansas & Colorado to Expand Footprint
by Zacks Equity Research
The acquisition deals increase ENSG's portfolio to encompass 323 healthcare operations spanning 14 states.
Are Investors Undervaluing Universal Health Services (UHS) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Reasons to Retain Cardinal Health Stock in Your Portfolio Now
by Zacks Equity Research
CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
Embecta Stock Gains on FDA Clearance for Type 2 Diabetes Insulin Pump
by Zacks Equity Research
EMBC's shares close higher following FDA clearance for its disposable patch pump for insulin delivery, expanding the target market with its availability for type 2 diabetes.
Greenville Center to Boost CAH Stock's at-Home Solution Business
by Zacks Equity Research
Cardinal Health announces the opening of its new distribution center in Greenville to support its at-Home Solutions business.
Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI
by Zacks Equity Research
FEMY's eco-friendly FemVue MINI receives CE Mark and Health Canada approval, advancing sustainable fallopian tube assessment technology in Europe and Canada.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL's strong product portfolio raises optimism about the stock.
Encompass Health Stock Rises 39.4% YTD: Should You Buy Now?
by Zacks Equity Research
To meet the increasing demand for its services, EHC is expected to continue adding beds.
Here's Why Universal Health Services (UHS) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Delcath Systems Stock Gains on Positive CHEMOSAT Melanoma Data
by Zacks Equity Research
DCTH's study of the CHEMOSAT Hepatic Delivery System shows that the device significantly boosts survival rates in uveal melanoma patients with liver metastases, outperforming systemic therapies.
DaVita Rallies 44% Year to Date: What's Driving the Stock?
by Zacks Equity Research
DVA's shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.
Tenet Healthcare Corporation (THC) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Tenet (THC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Centene Shifts an AcariaHealth Facility to Shelby Township
by Zacks Equity Research
The relocation of the facility is expected to enhance CNC's specialty pharmacy capabilities and patient care services.
QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod
by Zacks Equity Research
QDEL announces the FDA's clearance for its VITROS syphilis assay, which boosts the company's infectious disease testing portfolio.
iRhythm Technologies Launches Zio Monitoring Across Europe
by Zacks Equity Research
IRTC launches Zio monitor in Austria, Netherlands, Spain and Switzerland, which offers 14-day continuous ECG monitoring, enhancing arrhythmia diagnosis and patient care.
Universal Health Services, Inc. (UHS) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
5 Relative Price Strength Stocks That You Should Buy Now
by Nilanjan Choudhury
SNCR, MCY, UHS, VCYT and MWA are five stocks with explosive relative price strength.
Veeva Systems Q2 Earnings & Revenues Beat, Operating Margin Up Y/Y
by Zacks Equity Research
VEEV's fiscal second-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.
Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits
by Zacks Equity Research
MRVI's Cygnus and TriLink introduce AccuRes kits, setting a new standard in host cell DNA quantification with unmatched sensitivity and specificity.
Tenet Stock Rises 24.6% in 3 Months: Is This Your Buy Signal?
by Kaibalya Pravo Dey
Despite the recent growth in stock price, THC is trading at a discount compared to the industry average.
Accuray Stock Rises After Helix System Wins CE Mark for Cancer Care
by Zacks Equity Research
ARAY's Helix system, now CE Mark approved, aims to close global cancer care gaps with cost-effective, high-throughput radiotherapy for underserved regions.
Stryker Rallies 19.8% Year to Date: What's Driving the Stock?
by Zacks Equity Research
SYK's flagship Mako Total Knee Platform, its strategic acquisitions and a diversified product portfolio raise optimism about the stock.
AtriCure's Shares Likely to Benefit From New AtriClip Device Sales
by Zacks Equity Research
ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device.